Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, has priced a $21 million underwritten public offering, a move that underscores the substantial capital required to advance late-stage clinical trials for neurodegenerative diseases. The offering consists of 19 million common shares, pre-funded warrants to purchase up to 2 million shares, and accompanying warrants to purchase up to 21 million shares. The combined offering price is $1 per common share and accompanying warrant, or $0.9999 per pre-funded warrant and accompanying warrant. The warrants have an exercise price of $1 per share and expire five years after issuance. The offering is expected to close on or about Nov. 6, 2026, subject to customary closing conditions, with Canaccord Genuity acting as sole bookrunner.
The net proceeds are earmarked primarily to support continued clinical development of buntanetap, Annovis's investigational oral therapy for Alzheimer's disease and Parkinson's disease, as well as for working capital and general corporate purposes. Buntanetap (formerly posiphen) is a once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients.
The offering matters because it provides Annovis with the financial runway to continue Phase 3 development at a time when investors are closely watching cash positions among small-cap biotechs. Neurodegenerative disease trials are notoriously lengthy and expensive, and a $21 million infusion, while modest by big-pharma standards, can extend the company's ability to generate the data needed for regulatory submissions. For patients and caregivers, the funding represents continued momentum for a drug candidate that, if successful, could offer a disease-modifying approach rather than merely symptomatic relief.
Annovis Bio is headquartered in Malvern, Pennsylvania, and its shares trade on the New York Stock Exchange under the ticker ANVS. The offering's structure, including pre-funded warrants, is a common mechanism for investors who face ownership limitations, and the accompanying warrants could provide additional capital if exercised. However, the company noted that the gross proceeds figure excludes potential proceeds from warrant exercises and is before deducting offering expenses, meaning the actual net amount available for development will be lower.
For those tracking the company, the full press release is available at https://ibn.fm/DGBQK, and additional information can be found at www.annovisbio.com. The company also maintains a presence on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
This announcement is also a reminder of the role that specialized communications platforms play in disseminating material information to investors. BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement to ensure maximum impact. It also offers social media distribution and a full array of tailored corporate communications solutions. Such channels help ensure that developments like Annovis's offering reach a wide audience of investors, influencers, and the public.


